Abstract: Deucravacitinib (BMS-986165) is a novel, oral, highly selective allosteric inhibitor of tyrosine kinase 2 (TYK2), currently under investigation for the treatment of Inflammatory Bowel Disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC). Unlike traditional pan-Janus kinase (JAK) inhibitors that bind to the highly conserved active catalytic domain, deucravacitinib uniquely targets the regulatory pseudokinase (JH2) domain of TYK2. This allosteric mechanism provides exceptional selectivity, effectively blocking interleukin (IL)-12, IL-23, and type I interferon (IFN) signaling pathways without the off-target toxicities typically associated with JAK1-3 inhibition. While preclinical murine models demonstrated robust protection against colitis, Phase 2 clinical trials in IBD (such as LATTICE-UC and LATTICE-CD) have yielded mixed results, failing to meet primary clinical remission endpoints at standard doses. However, higher doses have shown promise in achieving stringent endoscopic remission. Notably, deucravacitinib exhibits a highly favorable cardiovascular safety profile in IBD patients, significantly reducing the risks of venous thromboembolism (VTE) and major adverse cardiovascular events (MACE). Future research is focused on optimizing dosing regimens to fully unlock its therapeutic potential in IBD.
1. Introduction
Inflammatory bowel diseases (IBD), encompassing Crohn's disease (CD) and ulcerative colitis (UC), are chronic, relapsing, immune-mediated inflammatory disorders of the gastrointestinal tract [2]. The pathogenesis of IBD is driven by a complex interplay of genetic and environmental factors that trigger dysregulated innate and adaptive immune responses [2]. Central to this inflammatory cascade are cytokines such as interleukin (IL)-12, IL-23, and type I interferons (IFNs), which rely on the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway for intracellular signal transduction [1][2].
While pan-JAK inhibitors have been utilized in IBD, they often yield inconsistent efficacy and are associated with significant toxicities—such as infections, laboratory abnormalities, and cardiovascular events—due to a lack of selectivity at therapeutic doses [2]. To address these safety concerns, selective inhibition of tyrosine kinase 2 (TYK2), a member of the JAK family, has emerged as a promising therapeutic strategy. Deucravacitinib (formerly BMS-986165) is a first-in-class, oral, highly selective TYK2 inhibitor [4]. Although already approved for the treatment of moderate-to-severe plaque psoriasis, its ability to broadly suppress Th1 and Th17-mediated inflammation positions it as a strong candidate for the management of IBD [1][2].
2. Pharmacological Activity
In preclinical studies, deucravacitinib demonstrated robust pharmacological activity against IBD. In murine models, prophylactic treatment with deucravacitinib resulted in dose-dependent inhibition of IL-12-mediated weight loss and prevented IL-12- and IL-23-dependent wasting and histologically confirmed colitis [2][4][5].
Clinically, deucravacitinib has been evaluated in several Phase 2 trials for IBD, including LATTICE-UC (NCT03934216), LATTICE-CD (NCT03599622), and IM011-127 (NCT04613518) [1][2]. In the LATTICE-UC trial involving patients with moderate-to-severe UC, deucravacitinib (6 mg twice daily) failed to meet its primary endpoint of clinical remission at week 12, achieving 14.8% remission compared to 16.3% in the placebo group [4]. Similarly, in the LATTICE-CD trial, clinical remission rates at week 12 were not statistically significant between the deucravacitinib and placebo groups [1]. Despite missing primary clinical endpoints, a signal of efficacy was observed at higher doses: in the 12 mg twice-daily group, endoscopic remission—a highly stringent objective outcome—was achieved in 28.0% of deucravacitinib-treated patients versus 0% in the placebo group [1].
From a safety perspective, deucravacitinib exhibits a highly favorable profile in IBD patients. A network meta-analysis evaluating the cardiovascular safety of JAK inhibitors in IBD found that deucravacitinib ranked the lowest for cardiovascular risks. It significantly decreased the risks of venous thromboembolism (VTE) and major adverse cardiovascular events (CVE/MACE) compared to placebo, distinguishing it from less selective JAK inhibitors [9].
3. Molecular Mechanism of Action
Deucravacitinib operates through a unique allosteric mechanism of action that is distinct from traditional JAK1-3 inhibitors [2][4]. Instead of binding directly to the active site in the catalytic (JH1) domain, deucravacitinib binds with high potency to the regulatory pseudokinase (JH2) domain of TYK2 [3][4]. This allosteric binding stabilizes an inhibitory interaction between the regulatory JH2 domain and the catalytic JH1 domain, effectively locking TYK2 in an inactive conformation [2][3].
By rendering TYK2 inactive, deucravacitinib prevents receptor-mediated activation and subsequent downstream signal transduction of key pro-inflammatory cytokines. Specifically, it blocks the intracellular signaling of IL-12, IL-23, and type I IFNs, thereby suppressing the activation of Th1 and Th17 cells and the subsequent production of inflammatory mediators that drive intestinal damage in IBD [1][2][5].
4. Structure-Activity Relationship (SAR)
The structural design of deucravacitinib is the foundation of its exceptional selectivity. The active catalytic (JH1) domain is highly conserved across all members of the JAK superfamily (JAK1, JAK2, JAK3, and TYK2), making it difficult for orthosteric inhibitors (which compete with ATP at the JH1 site) to achieve true selectivity [2][6]. In contrast, the regulatory pseudokinase (JH2) domain possesses unique structural features specific to TYK2 [2].
By specifically targeting the TYK2 JH2 domain, deucravacitinib achieves greater than 100-fold selectivity for TYK2 over JAK1 and JAK3, and greater than 2000-fold selectivity over JAK2 in cell-based assays [2][3]. This structural specificity ensures that deucravacitinib does not interfere with JAK1/2/3-dependent physiological processes, such as hematopoiesis or lipid metabolism, thereby avoiding the systemic toxicities (e.g., cytopenias, dyslipidemia) commonly seen with pan-JAK inhibitors [3][5].
5. Current Limitations
The primary limitation of deucravacitinib in the context of IBD is its failure to meet primary clinical efficacy endpoints in Phase 2 trials to date [1][3]. In both UC and CD trials, standard doses (e.g., 3 mg and 6 mg twice daily) did not demonstrate a statistically significant difference in clinical remission rates compared to placebo [1][4]. It is hypothesized that the doses utilized in these initial trials, which were based on efficacy in psoriasis, may have been suboptimal for intestinal inflammation. IBD typically requires higher doses of IL-23 pathway inhibitors to achieve mucosal healing compared to dermatological conditions [1]. Furthermore, the limited sample sizes in the higher-dose cohorts (e.g., 12 mg twice daily) restrict the statistical power needed to definitively confirm the observed endoscopic benefits [1].
6. Future Perspectives
Despite initial clinical setbacks, the mechanistic rationale for TYK2 inhibition in IBD remains strong. The observation that a higher dose (12 mg twice daily) induced endoscopic remission in 28% of patients suggests that deucravacitinib possesses therapeutic potential for IBD if the dosing regimen is optimized [1]. Future, larger-scale Phase 2b and Phase 3 clinical trials utilizing higher induction and maintenance doses are warranted to properly evaluate its efficacy in CD and UC [1].
Additionally, deucravacitinib's outstanding safety profile—particularly its lack of black-box warnings and its demonstrated ability to lower the risk of VTE and MACE in IBD patients—positions it as a highly desirable alternative to existing JAK inhibitors [9]. It holds significant promise as a safer, targeted oral therapy, especially for elderly IBD patients or those with pre-existing cardiovascular risk factors who cannot tolerate pan-JAK inhibitors [1][9].
